Q-omics provides the consensus-scored RPL23AP70 profile across patient tissues and cancer cell-line models. RPL23AP70 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL23AP70 is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, RPL23AP70 RNA expression shows 6,405 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, ESCA, and STAD as cancer lineages where RPL23AP70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP70 survival associations across molecular data types. RPL23AP70 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP70 RNA expression–survival associations across cancer types. High RPL23AP70 expression shows unfavorable associations in CHOL, KIRC, GBM, PRAD and STAD, but favorable associations in UCEC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL23AP70 RNA expression.
This table summarizes RPL23AP70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP70 shows lower tumor expression in ESCA and higher tumor expression in BRCA and KIRC. The ESCA box plot shows higher RPL23AP70 RNA expression in normal versus tumor tissue (log2 FC = −0.145, t-test p = .001).
This table shows molecular features associated with RPL23AP70 in patient tissues and cancer cell lines. In patient samples, RPL23AP70 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
